- Treatment with INO-3107 resulted in 16 of 21 (76%) participants with a reduction in number of surgical interventions compared with previous year; 6 participants required no surgical intervention during the trial
- INO-3107 demonstrated statistical significance based on clinical endpoint of reduction in overall number of surgical interventions compared with previous year
- INO-3107 was found to be well-tolerated and immunogenic
PLYMOUTH MEETING, PA, USA I October 13, 2022 I INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced positive interim results from an ongoing Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults. In the first cohort of 21 participants, INO-3107 showed a statistically significant improvement in the clinical endpoint of the number of surgical interventions needed to control papilloma growth. INO-3107 was also observed to be well-tolerated and immunogenic in the trial. INO-3107 received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in July 2020.
Dr. Jacqueline Shea, INOVIO’s President and CEO, said, “RRP is a debilitating, often life-long condition for which surgery is the standard of care and there are no currently FDA-approved therapeutic vaccines or drugs. The positive results observed in this trial are a step toward potentially shifting the treatment paradigm for RRP and substantially improving the quality of life for patients suffering from its symptoms and the repeated surgeries needed to control them. As a potential first-in-class therapeutic candidate, INO-3107 is building on our body of work indicating that DNA medicines have the potential to treat HPV-associated diseases.”
Dr. Ted Mau, Professor of Otolaryngology, Head and Neck Surgery at UT Southwestern Medical Center and investigator for INOVIO’s RRP Phase 1/2 clinical trial, said, “These preliminary results show great promise in this new therapy for patients with RRP. For our patients who have required multiple surgeries a year, and especially those who have done so for many years of their lives, this is a potential game changer.”
About the Trial
INO-3107 was evaluated in a Phase 1/2 open-label, multicenter trial to assess its safety, tolerability, immunogenicity, and efficacy in 32 participants with HPV 6 and/or HPV 11-associated RRP (NCT:04398433). The trial demonstrated statistical significance based on the clinical endpoint of a reduction in the number of RRP surgical interventions in the year following administration of INO-3107 compared with the year prior to treatment, in the initial cohort of 21 participants. In the trial, there was a median decrease of 3 surgical interventions (95% confidence interval 1, 3). In addition, 16 of 21 (76%) participants showed a decrease in surgical interventions in the year following administration of INO-3107 relative to the number of surgeries in the year prior to the trial. Of the 16 participants, six (6) required no surgical intervention during the trial period.
In the trial, treatment with INO-3107 induced cellular responses against both HPV 6 and HPV 11, inducing both CD4 and CD8 T cells. All 21 participants demonstrated an increase in peripheral T cells to one or more antigens in INO-3107 post-baseline. T-cell responses against HPV 6 and HPV 11 were also still observed at Week 52, which was 43 weeks after treatment with INO-3107, indicating a persistent cellular memory response.
INO-3107 was well-tolerated, with all participants completing the trial follow-up. Treatment-emergent adverse events (TEAEs) observed in the trial were generally low-grade, with 86% of participants experiencing at least one TEAE, most of which were Grade 1. Three participants (14%) experienced a Grade 3 TEAE, but none were deemed related to INO-3107. The most commonly reported TEAEs were injection site pain (38%) and fatigue (19%). While two serious adverse events were reported, these were also deemed unrelated to INO-3107.
Dr. Jeffrey Skolnik, INOVIO’s Senior Vice President of Clinical Development, said, “We are very encouraged by the results of the Phase 1/2 trial, where we observed a median reduction of three surgical interventions from the year prior, with six participants being surgery-free, after receiving treatment with INO-3107 during the trial. We believe the ability of INO-3107 to induce antigen-specific immune responses may play an important role in the future treatment of RRP.”
Results from the second cohort of 11 patients are expected in the first half of 2023.
About RRP
RRP is a debilitating and rare disease caused primarily by HPV types 6 and/or 11. RRP is characterized by the development of small, wart-like growths, or papillomas, in the respiratory tract. While papillomas are generally benign, they can cause severe, life-threatening airway obstruction and respiratory complications. RRP can also significantly affect quality of life for patients by affecting the voicebox, limiting the ability to speak effectively. In RRP, the papillomas have a tendency to grow back after they have been removed surgically, which is the current standard of care, because the underlying HPV infection is not eradicated.
The incidence of RRP is rapidly changing, but has previously been estimated to be 4.3 per 100,000 children and 1.8 per 100,000 adults. RRP is often a life-long disease that affects both children and adults. Patients may undergo numerous surgeries during their lifetimes to control their RRP.
About INO-3107
INO-3107 is INOVIO’s clinical-stage DNA medicine product candidate being developed as a potential treatment for RRP. INO-3107 is designed to elicit a targeted T cell response against HPV 6 and HPV 11, the HPV types responsible for causing RRP among other HPV-associated diseases. These targeted T cells seek out and kill infected cells, leading potentially to a regression of existing papillomas and the possibility of clearing or reducing the levels of the virus which could prevent or slow the growth of new papillomas. The U.S. FDA granted Orphan Drug Designation for INO-3107 for the treatment of RRP in 2020. For more information about our HPV franchise, please visit https://ir.inovio.com/investors-and-media/default.aspx.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from infectious diseases, cancer, and diseases associated with HPV. Our DNA medicines in development are delivered using our investigational proprietary smart device to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com.
SOURCE: Inovio Pharmaceuticals
Post Views: 393
- Treatment with INO-3107 resulted in 16 of 21 (76%) participants with a reduction in number of surgical interventions compared with previous year; 6 participants required no surgical intervention during the trial
- INO-3107 demonstrated statistical significance based on clinical endpoint of reduction in overall number of surgical interventions compared with previous year
- INO-3107 was found to be well-tolerated and immunogenic
PLYMOUTH MEETING, PA, USA I October 13, 2022 I INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced positive interim results from an ongoing Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults. In the first cohort of 21 participants, INO-3107 showed a statistically significant improvement in the clinical endpoint of the number of surgical interventions needed to control papilloma growth. INO-3107 was also observed to be well-tolerated and immunogenic in the trial. INO-3107 received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in July 2020.
Dr. Jacqueline Shea, INOVIO’s President and CEO, said, “RRP is a debilitating, often life-long condition for which surgery is the standard of care and there are no currently FDA-approved therapeutic vaccines or drugs. The positive results observed in this trial are a step toward potentially shifting the treatment paradigm for RRP and substantially improving the quality of life for patients suffering from its symptoms and the repeated surgeries needed to control them. As a potential first-in-class therapeutic candidate, INO-3107 is building on our body of work indicating that DNA medicines have the potential to treat HPV-associated diseases.”
Dr. Ted Mau, Professor of Otolaryngology, Head and Neck Surgery at UT Southwestern Medical Center and investigator for INOVIO’s RRP Phase 1/2 clinical trial, said, “These preliminary results show great promise in this new therapy for patients with RRP. For our patients who have required multiple surgeries a year, and especially those who have done so for many years of their lives, this is a potential game changer.”
About the Trial
INO-3107 was evaluated in a Phase 1/2 open-label, multicenter trial to assess its safety, tolerability, immunogenicity, and efficacy in 32 participants with HPV 6 and/or HPV 11-associated RRP (NCT:04398433). The trial demonstrated statistical significance based on the clinical endpoint of a reduction in the number of RRP surgical interventions in the year following administration of INO-3107 compared with the year prior to treatment, in the initial cohort of 21 participants. In the trial, there was a median decrease of 3 surgical interventions (95% confidence interval 1, 3). In addition, 16 of 21 (76%) participants showed a decrease in surgical interventions in the year following administration of INO-3107 relative to the number of surgeries in the year prior to the trial. Of the 16 participants, six (6) required no surgical intervention during the trial period.
In the trial, treatment with INO-3107 induced cellular responses against both HPV 6 and HPV 11, inducing both CD4 and CD8 T cells. All 21 participants demonstrated an increase in peripheral T cells to one or more antigens in INO-3107 post-baseline. T-cell responses against HPV 6 and HPV 11 were also still observed at Week 52, which was 43 weeks after treatment with INO-3107, indicating a persistent cellular memory response.
INO-3107 was well-tolerated, with all participants completing the trial follow-up. Treatment-emergent adverse events (TEAEs) observed in the trial were generally low-grade, with 86% of participants experiencing at least one TEAE, most of which were Grade 1. Three participants (14%) experienced a Grade 3 TEAE, but none were deemed related to INO-3107. The most commonly reported TEAEs were injection site pain (38%) and fatigue (19%). While two serious adverse events were reported, these were also deemed unrelated to INO-3107.
Dr. Jeffrey Skolnik, INOVIO’s Senior Vice President of Clinical Development, said, “We are very encouraged by the results of the Phase 1/2 trial, where we observed a median reduction of three surgical interventions from the year prior, with six participants being surgery-free, after receiving treatment with INO-3107 during the trial. We believe the ability of INO-3107 to induce antigen-specific immune responses may play an important role in the future treatment of RRP.”
Results from the second cohort of 11 patients are expected in the first half of 2023.
About RRP
RRP is a debilitating and rare disease caused primarily by HPV types 6 and/or 11. RRP is characterized by the development of small, wart-like growths, or papillomas, in the respiratory tract. While papillomas are generally benign, they can cause severe, life-threatening airway obstruction and respiratory complications. RRP can also significantly affect quality of life for patients by affecting the voicebox, limiting the ability to speak effectively. In RRP, the papillomas have a tendency to grow back after they have been removed surgically, which is the current standard of care, because the underlying HPV infection is not eradicated.
The incidence of RRP is rapidly changing, but has previously been estimated to be 4.3 per 100,000 children and 1.8 per 100,000 adults. RRP is often a life-long disease that affects both children and adults. Patients may undergo numerous surgeries during their lifetimes to control their RRP.
About INO-3107
INO-3107 is INOVIO’s clinical-stage DNA medicine product candidate being developed as a potential treatment for RRP. INO-3107 is designed to elicit a targeted T cell response against HPV 6 and HPV 11, the HPV types responsible for causing RRP among other HPV-associated diseases. These targeted T cells seek out and kill infected cells, leading potentially to a regression of existing papillomas and the possibility of clearing or reducing the levels of the virus which could prevent or slow the growth of new papillomas. The U.S. FDA granted Orphan Drug Designation for INO-3107 for the treatment of RRP in 2020. For more information about our HPV franchise, please visit https://ir.inovio.com/investors-and-media/default.aspx.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from infectious diseases, cancer, and diseases associated with HPV. Our DNA medicines in development are delivered using our investigational proprietary smart device to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com.
SOURCE: Inovio Pharmaceuticals
Post Views: 393
